SCHEMBL4248727

SCHEMBL4248727

CC(=O)c1cccc(S(=O)(=O)C(N)c2ccccc2-c2ccccc2C(=O)NCc2ccccc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
HSD17B10 Q99714 1/20 0.50
HTT P42858 1/20 0.47
POLB P06746 1/20 0.46
CHRNB2 P17787 1/20 0.45
CHRNB4 P30926 1/20 0.45
CHRNA3 P32297 1/20 0.45
CHRNA4 P43681 1/20 0.45
RAB9A P51151 2/20 0.44
ITGA4 P13612 1/20 0.43
ITGB7 P26010 1/20 0.43
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MAPK1 P28482 2/20 0.41
CA4 P22748 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KCNA5 P22460 1/20 0.41
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242916 0.86 CHRNB2 (0.46) ALDH1A1GAAHSD17B10HTTCHRNB2
SCHEMBL4248643 0.80 CA1 (0.46) ALDH1A1RAB9AMEN1KMT2AKCNA5
SCHEMBL2204497 0.78 HTT (0.62) ALDH1A1GAAHSD17B10HTTPOLB
SCHEMBL4245385 0.77 RAB9A (0.46) ALDH1A1POLBRAB9AKCNA5LMNA
SCHEMBL4247417 0.74 ALDH1A1 (0.53) ALDH1A1RAB9AMEN1KMT2ALMNA
SCHEMBL4236018 0.73 ALDH1A1 (0.50) ALDH1A1POLBRAB9AKMT2AKCNA5
SCHEMBL4240832 0.70 ALDH1A1 (0.41) ALDH1A1GAAHTTPOLBHDAC8
SCHEMBL4240140 0.69 GBA1 (0.43) ALDH1A1GAAHTTMEN1KMT2A
SCHEMBL14947453 0.68 HDAC2 (0.73) ALDH1A1HTTPOLBRAB9AHDAC8
SCHEMBL7828799 0.67 KMT2A (0.77) GAAHTTCHRNB2CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2004-05-27 US disclosed
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, KCNH1 ALDH1A1 217/4885GAA 4224/4885HSD17B10 3045/4885
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, CACNA1E ALDH1A1 213/4885GAA 4265/4885HSD17B10 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.